Royal DSM N.V. and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a non-exclusive PER.C6® research licensing agreement with Moscow, Russia-based Masterclone. Masterclone will use Crucell's technology to develop an undisclosed antibody. No financial details to be disclosed.
About the PER.C6® Technology Platform
Crucell's and DSM's PER.C6® technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as vaccines and proteins. Compared to conventional production technologies, the strengths of the PER.C6® technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.
Reactie XEA.nl
Dit bericht is eigenlijk laat, gisteren liep de koers van Crucell er al op vooruit.